Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2-(5-hydroxy-naphthalen-1-yl)-1,3-benzoxazol‑6‑ol is an experimental small molecule belonging to the naphthol and benzoxazole chemical classes. It has demonstrated biological activity as a selective estrogen receptor modulator (SERM), with high affinity for both human estrogen receptor beta (ERβ) and alpha (ERα). In vitro studies show potent inhibition of ERβ (IC50 ≈ 5 nM) and moderate inhibition of ERα (IC50 ≈ 117 nM), suggesting potential utility in modulating estrogenic pathways. The compound has not been approved for any indication and remains at the experimental stage[1][8]. No clinical trials or marketed formulations are reported.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-(5-hydroxy-naphthalen-1-yl)-1,3-benzoxazol-6-ol.